Huntingtin Aggregation Kinetics and Their Pathological Role in a Drosophila Huntington's Disease Model

被引:69
|
作者
Weiss, Kurt R. [1 ,2 ]
Kimura, Yoko [1 ,2 ,3 ]
Lee, Wyan-Ching Mimi [1 ,2 ]
Littleton, J. Troy [1 ,2 ]
机构
[1] MIT, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA
[2] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA
[3] Tokyo Metropolitan Inst Med Sci, Lab Prot Metab, Setagaya Ku, Tokyo 1568506, Japan
关键词
NEURONAL INTRANUCLEAR INCLUSIONS; TRANSGENIC MOUSE MODEL; N-TERMINAL HUNTINGTIN; MUTANT HUNTINGTIN; AXONAL-TRANSPORT; CELL-DEATH; IN-VIVO; POLYGLUTAMINE DISEASE; TRINUCLEOTIDE REPEAT; CHAPERONES REDUCE;
D O I
10.1534/genetics.111.133710
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Huntington's disease is a neurodegenerative disorder resulting from expansion of a polyglutamine tract in the Huntingtin protein. Mutant Huntingtin forms intracellular aggregates within neurons, although it is unclear whether aggregates or more soluble forms of the protein represent the pathogenic species. To examine the link between aggregation and neurodegeneration, we generated Drosophila melanogaster transgenic strains expressing fluorescently tagged human huntingtin encoding pathogenic (Q138) or nonpathogenic (Q15) proteins, allowing in vivo imaging of Huntingtin expression and aggregation in live animals. Neuronal expression of pathogenic Huntingtin leads to pharate adult lethality, accompanied by formation of large aggregates within the cytoplasm of neuronal cell bodies and neurites. Live imaging and Fluorescence Recovery After Photobleaching (FRAP) analysis of pathogenic Huntingtin demonstrated that new aggregates can form in neurons within 12 hr, while preexisting aggregates rapidly accumulate new Huntingtin protein within minutes. To examine the role of aggregates in pathology, we conducted haplo-insufficiency suppressor screens for Huntingtin-Q138 aggregation or Huntingtin-Q138-induced lethality, using deficiencies covering similar to 80% of the Drosophila genome. We identified two classes of interacting suppressors in our screen: those that rescue viability while decreasing Huntingtin expression and aggregation and those that rescue viability without disrupting Huntingtin aggregation. The most robust suppressors reduced both soluble and aggregated Huntingtin levels, suggesting toxicity is likely to be associated with both forms of the mutant protein in Huntington's disease.
引用
收藏
页码:581 / U488
页数:25
相关论文
共 50 条
  • [31] Huntingtin aggregation in motor neurons: Two Huntington's disease patients who developed motor neuron disease
    Coon, Elizabeth A.
    Osmand, Alexander P.
    Kirby, Patricia A.
    Martin, Wayne
    Wieler, Marguerite
    Paulson, Henry L.
    ANNALS OF NEUROLOGY, 2007, 62 : S14 - S14
  • [32] Huntingtin aggregation in motor neurons: Two Huntington's disease patients who developed motor neuron disease
    Coon, E.
    Kirby, P.
    Martin, W.
    Wieler, M.
    Osmand, A.
    Paulson, H.
    MOVEMENT DISORDERS, 2007, 22 (12) : III - IV
  • [33] Effects of ginseng and ginsenosides on mutant huntingtin aggregation, cellular apoptosis, mitochondrial dysfunction and motor impairment of Huntington's disease model
    Ban, J. J.
    Im, W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S399 - S399
  • [34] Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice
    Li, H
    Li, SH
    Yu, ZX
    Shebourne, P
    Li, XJ
    JOURNAL OF NEUROSCIENCE, 2001, 21 (21): : 8473 - 8481
  • [35] Huntingtin-lowering strategies for Huntington's disease
    Barker, Roger A.
    Fujimaki, Motoki
    Rogers, Priya
    Rubinsztein, David C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1125 - 1132
  • [36] Huntington's disease: Huntingtin and the control of axonal transport
    Zala, D.
    Liot, G.
    Humbert, S.
    Saudou, F.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 60 - 60
  • [37] Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease
    Tabrizi, Sarah J.
    Ghosh, Rhia
    Leavitt, Blair R.
    NEURON, 2019, 101 (05) : 801 - 819
  • [38] Targeting Huntingtin in Patients with Huntington's Disease Reply
    Tabrizi, Sarah J.
    Smith, Anne V.
    Bennett, C. Frank
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12): : 1181 - 1182
  • [39] SUMO modification of Huntingtin and Huntington's disease pathology
    Steffan, JS
    Agrawal, N
    Pallos, J
    Rockabrand, E
    Trotman, LC
    Slepko, N
    Illes, K
    Lukacsovich, T
    Zhu, YZ
    Cattaneo, E
    Pandolfi, PP
    Thompson, LM
    Marsh, JL
    SCIENCE, 2004, 304 (5667) : 100 - 104
  • [40] Targeting Huntingtin Expression in Patients with Huntington's Disease
    Tabrizi, Sarah J.
    Leavitt, Blair R.
    Landwehrmeyer, G. Bernhard
    Wild, Edward J.
    Saft, Carsten
    Barker, Roger A.
    Blair, Nick F.
    Craufurd, David
    Priller, Josef
    Rickards, Hugh
    Rosser, Anne
    Kordasiewicz, Holly B.
    Czech, Christian
    Swayze, Eric E.
    Norris, Daniel A.
    Baumann, Tiffany
    Gerlach, Irene
    Schobel, Scott A.
    Paz, Erika
    Smith, Anne V.
    Bennett, C. Frank
    Lane, Roger M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2307 - 2316